Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by TheracosBio

News headline image
TheracosBio Collaborates with Publix Pharmacy to Provide Affordably Priced FDA-approved Diabetes Medication
From TheracosBio
Via Business Wire
News headline image
A Study in the New Issue of JAMA Network Open Reveals Income-Related Disparities in Type 2 Diabetes Outcomes Despite Equivalent Access to Healthcare
From TheracosBio
Via Business Wire
News headline image
TheracosBio is a Proud Sponsor of  the Inaugural Achieving Diabetes Equity in Practice Today (ADEPT) Conference
From TheracosBio
Via Business Wire
News headline image
TheracosBio and BAMCO Africa Partner to Bring Affordably Priced Diabetes Medication to Sub-Saharan Africa
From TheracosBio
Via Business Wire
News headline image
TheracosBio Partners with PBA Health to Provide Affordably Priced FDA-approved Diabetes Medication to Thousands of Independent Community Pharmacies
From TheracosBio
Via Business Wire
News headline image
Release of Negotiated Prices Under Inflation Reduction Act Reveals that BRENZAVVY® (bexagliflozin) Remains the Lowest Priced SGLT2 Inhibitor
From TheracosBio
Via Business Wire
News headline image
Head-to-Head Study Finds TheracosBio's BRENZAVVY® (bexagliflozin) Non-Inferior to Dapagliflozin in Chinese Patients With Type 2 Diabetes
From TheracosBio
Via Business Wire
News headline image
TheracosBio Extends Partnership with Mark Cuban Cost Plus Drug Company
From TheracosBio
Via Business Wire
News headline image
CV Safety Profile of TheracosBio’s BRENZAVVY® (bexagliflozin) Confirmed in Research Published in Diabetes, Obesity and Metabolism
From TheracosBio
Via Business Wire
News headline image
TheracosBio, IPC Announce Distribution Partnership to Make BRENZAVVY® (bexagliflozin) Available to Thousands of IPC Member Pharmacies
From TheracosBio
Via Business Wire
News headline image
TheracosBio Announces Royalty Financing Agreement with HealthCare Royalty
From TheracosBio
Via Business Wire
News headline image
TheracosBio and SmithRx Collaborate to Offer Newly Approved Diabetes Drug Brenzavvy™ (bexagliflozin) to Members with Type 2 Diabetes
From TheracosBio
Via Business Wire
News headline image
TheracosBio Announces Publication of Data on the Safety and Effectiveness of Brenzavvy™ (bexagliflozin) as an Adjunct to Metformin
From TheracosBio
Via Business Wire
News headline image
TheracosBio Appoints Brian Connelly as Chief Executive Officer
From TheracosBio
Via Business Wire
News headline image
TheracosBio Announces Commercial Availability of Brenzavvy™ (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes
From TheracosBio
Via Business Wire
News headline image
TheracosBio Announces the Appointments of Jim Greenwood to Board of Directors and Jeff McGroarty as Chief Financial Officer
From TheracosBio
Via Business Wire
News headline image
TheracosBio Announces FDA Approval of Brenzavvy™ (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes
From TheracosBio
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.